Understand the source comparison
Best Peptides to Lose Weight After 40 Ranked: Clinical Evidence Comparison
Tirzepatide (15mg weekly) Dual GLP-1/GIP receptor agonist. Delays gastric emptying, extends satiety, potentiates insulin secretion 20.9% at 72 weeks (SURMOUNT-1) GI side effects in 40–50% during titration; pancreatitis risk <1% FDA-approved (Zepbound, Mounjaro
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tirzepatide (15mg weekly)
- Dual GLP-1/GIP receptor agonist. Delays gastric emptying, extends satiety, potentiates insulin secretion
- 20.9% at 72 weeks (SURMOUNT-1)
- GI side effects in 40–50% during titration; pancreatitis risk <1%
- FDA-approved (Zepbound, Mounjaro)
- Strongest clinical evidence for weight loss after 40. Dual incretin mechanism outperforms single-agonist GLP-1 drugs consistently
- Semaglutide (2.4mg weekly)
- GLP-1 receptor agonist. Slows gastric emptying, reduces appetite via hypothalamic signaling
- 14.9% at 68 weeks (STEP-1)
- Nausea, vomiting, diarrhea in 44%; contraindicated in MTC or MEN2 history
- FDA-approved (Wegovy, Ozempic)
- Gold standard single-agonist GLP-1. Proven efficacy across ages 18–75 with robust safety profile
- CJC-1295 + Ipamorelin (300mcg/300mcg nightly)
- GH secretagogue combination. Restores pulsatile GH secretion without cortisol elevation
- 6–9% visceral fat reduction over 12 weeks (when paired with resistance training)
- Transient water retention, flushing at injection site; no cortisol or prolactin elevation
- Research-grade (not FDA-approved for weight loss)
- Best option for body recomposition in adults over 40 already training. Indirect fat loss via increased lean mass and lipolysis
- MK-677 (25mg daily)
- Oral ghrelin receptor agonist. Elevates basal GH and IGF-1 without suppressing endogenous GHRH
- 0.4kg visceral fat reduction, 1.1kg lean mass gain over 12 months (adults 60–81 years)
- Mild fasting hyperglycemia in 15%; transient water retention first 4–6 weeks
- Research-grade
- Works best for lean mass preservation during caloric deficit. Minimal direct fat loss without structured diet and training
- Tesofensine (1.0mg daily)
- Triple monoamine reuptake inhibitor. Increases NEAT and thermogenesis via norepinephrine activity
- 12.8% at 24 weeks (Phase 2 trial)
- Insomnia, dry mouth, elevated heart rate in 20–30%; contraindicated in cardiovascular disease
- Phase 2 (not FDA-approved)
- Effective for NEAT-driven weight loss but cardiovascular risk limits broader use. Currently unavailable outside clinical trials
- Lipo-C (weekly IM injection)
- Lipotropic agent (methionine, inositol, choline). Supports hepatic lipid export via VLDL assembly
- No direct weight loss data; supports fat metabolism indirectly by preventing hepatic steatosis
- Minimal; injection site soreness
- Not classified as drug
- Adjunct to diet and exercise. Addresses choline deficiency common in adults over 40 but not a standalone weight loss compound